- Home
- INCY vs COHR Comparison
INCY vs COHR Comparison
Compare INCY & COHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- COHR
- Stock Information
- Founded
- INCY 1991
- COHR 1971
- Country
- INCY United States
- COHR United States
- Employees
- INCY N/A
- COHR N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- COHR Electronic Components
- Sector
- INCY Health Care
- COHR Technology
- Exchange
- INCY Nasdaq
- COHR Nasdaq
- Market Cap
- INCY 13.0B
- COHR 14.5B
- IPO Year
- INCY 1993
- COHR 1987
- Fundamental
- Price
- INCY $86.64
- COHR $97.81
- Analyst Decision
- INCY Buy
- COHR Strong Buy
- Analyst Count
- INCY 20
- COHR 16
- Target Price
- INCY $80.31
- COHR $109.40
- AVG Volume (30 Days)
- INCY 1.7M
- COHR 5.9M
- Earning Date
- INCY 10-28-2025
- COHR 11-05-2025
- Dividend Yield
- INCY N/A
- COHR N/A
- EPS Growth
- INCY 900.04
- COHR N/A
- EPS
- INCY 4.37
- COHR N/A
- Revenue
- INCY $4,584,996,000.00
- COHR $5,810,115,000.00
- Revenue This Year
- INCY $16.26
- COHR $10.57
- Revenue Next Year
- INCY $11.07
- COHR $7.08
- P/E Ratio
- INCY $19.84
- COHR N/A
- Revenue Growth
- INCY 18.87
- COHR 23.42
- 52 Week Low
- INCY $53.56
- COHR $45.58
- 52 Week High
- INCY $87.99
- COHR $123.25
- Technical
- Relative Strength Index (RSI)
- INCY 64.89
- COHR 53.52
- Support Level
- INCY $83.41
- COHR $85.94
- Resistance Level
- INCY $87.99
- COHR $95.97
- Average True Range (ATR)
- INCY 1.68
- COHR 3.58
- MACD
- INCY -0.37
- COHR 0.20
- Stochastic Oscillator
- INCY 70.52
- COHR 81.71
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About COHR Coherent Corp.
Coherent Corp engaged in materials, networking, and lasers, is a vertically integrated manufacturing company that develops, manufactures, and markets engineered materials, optoelectronic components and devices, and lasers for use in the industrial, communications, electronics and instrumentation markets. The firm operates in three segments Networking, Materials, and Lasers Segment. It generates maximum revenue from Networking segment. The company geographically operates in North America. Europe, China, Japan and Rest of the world.